A prospective study analyzing short term effects of intravitreal versus intracameral bevacizumab on neovascular glaucoma

Medical Forum Monthly

Volumn 28, Issue 4, 2017, Pages 9-12

  Bodla, Ali Afzal ^a   Bodla, Muhammad Afzal ^a  

^a Multan Medical and Dental College ^*  (Pakistan)

Author keywords

Intracameral Bevacizumab; Intravitreal; Neovascular Glaucoma

Indexed keywords

BEVACIZUMAB; OFLOXACIN;

ABRASION; ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; COMPARATIVE STUDY; CORNEA INJURY; DRUG EFFICACY; FEMALE; HUMAN; INCIDENCE; INTERVENTION STUDY; INTRAOCULAR PRESSURE; MALE; NEOVASCULAR GLAUCOMA; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROLIFERATIVE DIABETIC RETINOPATHY; PROSPECTIVE STUDY; SHORT COURSE THERAPY; VERY ELDERLY; VISUAL ACUITY;

EID: 85026818347     PISSN: 1029385X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Moraczewski AL, Lee RK, Palmberg PF, et al. Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab. Br J Ophthalmol 2009;93:589-593.
2. Wakabayashi T, Oshima Y, Sakaguchi H, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal disease in 41 consecutive cases. Ophthalmol 2008;115(9): 1571-1580.
3. Duch S, Buchacra O, Milla E, Andreu D, Tellez J. Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients. J Glaucoma 2009;18(2):140-143.
4. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina 2006; 26:354-356.
5. Yuzbasioglu E, Artunay O, Rasier R, Sengul A, Bahcecioglu H. Simultaneous intravitreal and intracameral injection of bevacizumab (Avastin) in neovascular glaucoma. Ocul Pharmacol Ther 2009; 25(3):259-264.
6. Alkawas AA, Shahien EA, Hussein AM. Simultaneous intravitreal and intracameral injection of bevacizumab (Avastin) in neovascular glaucoma. J Ocul Pharmacol Ther 2009;25(3): 259-264.
7. Toklu Y, Cakmak HB, Raza S, Anayol A, Asik E, Simsek S. Short-term effects of intravitreal bevacizumab (Avastin(®)) on retrobulbar hemodynamics in patients with neovascular agerelated macular degeneration. Acta Ophthalmol 2011;89:41-45.
8. Bhagat PR, Agrawal KU, Tandel D. Study of the Effect of Injection Bevacizumab through Various Routes in Neovascular Glaucoma. J Curr Glaucoma Pract 2016;10(2):39-48.
9. Ungureanu E, Geamanu A, Popescu V, Dinu I, Grecescu M, Gradinaru S. Comparison between the efficacy and side effects of intravitreal versus anterior chamber Bevacizumab injection in neovascular glaucoma patients. J Med Life 2014; 7 (Spec Iss 4): 68-70.
10. Parodi M, Iacono P. Photodynamic therapy for neovascular glaucoma. Ophthalmol 2005;112: 1844-1845.
11. Avery R. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin®) treatment. Retina 2006;26:351-354.
12. Davidorf F, Mouser G, Derick R. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin®) injection. Retina 2006; 26:354-356.
13. Paula S, Jorge R, Costa A, Rodrigues Mde L, Scott IU. Short-term results of intravitreal bevacizumab (Avastin®) on anterior segment neovascularization in neovascular glaucoma. Acta Ophthalmol Scand 2006;84:556-557.
14. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006;142:158-160
15. Mason J, Albert M, Mays A, Vail R. Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina 2006;26:839-841.
16. Batioglu B, Astam N, Özmert E. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma. Int Ophthalmol 2008;28: 59-61.
17. Lee SJ, Lee JJ, Kin SY, Kim SD. Intravitreal bevacizumab (Avastin®) treatment of neovascular glaucoma in ocular ischemic syndrome. Korean J Ophthalmol 2009;23:132-134.
18. Hasanreisoglu M, Weinberger D, Mimouni K, et al. Intravitreal bevacizumab as an adjunct treatment for neovascular glaucoma. Eur J Ophthalmol 2009; 19:607-612.
19. Gupta V, Jha R, Rao A, Kong G, Sihota R. The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma. Eur J Ophthalmol 2009;19:435-441.
20. Jaissle G, Szurman P, Bartz-Schmit K. Recommendation for the implementation of intravitreal injections-statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA) Klin Monatsbl Augenheilkd 2005;225: 390-395.
21. Iliev M, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra G. Intravitreal bevacizumab (Avastin®) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006;142:1054-1056.